Diasorin Stock Return On Asset
| 34D Stock | EUR 99.76 0.00 0.00% |
DIASORIN fundamentals help investors to digest information that contributes to DIASORIN's financial success or failures. It also enables traders to predict the movement of DIASORIN Stock. The fundamental analysis module provides a way to measure DIASORIN's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to DIASORIN stock.
DIASORIN |
DIASORIN Company Return On Asset Analysis
DIASORIN's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, DIASORIN has a Return On Asset of 0.0. This indicator is about the same for the Other average (which is currently at 0.0) sector and about the same as Other (which currently averages 0.0) industry. This indicator is about the same for all Germany stocks average (which is currently at 0.0).
DIASORIN Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DIASORIN's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DIASORIN could also be used in its relative valuation, which is a method of valuing DIASORIN by comparing valuation metrics of similar companies.DIASORIN is currently under evaluation in return on asset category among its peers.
DIASORIN Fundamentals
| Current Valuation | 8.21 B | |||
| Price To Book | 4.51 X | |||
| Price To Sales | 5.18 X | |||
| Revenue | 1.24 B | |||
| EBITDA | 517.3 M | |||
| Net Income | 310.97 M | |||
| Total Debt | 1.23 B | |||
| Cash Flow From Operations | 400.66 M | |||
| Price To Earnings To Growth | 176.54 X | |||
| Number Of Employees | 29 | |||
| Market Capitalization | 9.85 B | |||
| Total Asset | 3.23 B | |||
| Z Score | 4.8 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 3.23 B | |||
| Last Dividend Paid | 0.9 |
About DIASORIN Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze DIASORIN's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DIASORIN using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DIASORIN based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in DIASORIN Stock
DIASORIN financial ratios help investors to determine whether DIASORIN Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DIASORIN with respect to the benefits of owning DIASORIN security.